Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for AstraZeneca Pharma India's Debt-to-Equity or its related term are showing as below:
NSE:ASTRAZEN'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.03 Max: 0.13
Current: 0.13
During the past 13 years, the highest Debt-to-Equity Ratio of AstraZeneca Pharma India was 0.13. The lowest was 0.01. And the median was 0.03.
NSE:ASTRAZEN's Debt-to-Equity is ranked better than 67.32% of 814
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs NSE:ASTRAZEN: 0.13
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
AstraZeneca Pharma India Debt-to-Equity Related Terms
AstraZeneca Pharma India Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AstraZeneca Pharma India Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where AstraZeneca Pharma India's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AstraZeneca Pharma India (NSE:ASTRAZEN) has a Debt-to-Equity of 0.13 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on AstraZeneca Pharma India and its competitors. This is 333% above median its historical median of 0.03. Over the past decade, AstraZeneca Pharma India's Debt-to-Equity has ranged from 0.01 to 0.13. According to the industry distribution chart, AstraZeneca Pharma India ranks #266 out of 814 companies in the Drug Manufacturers industry, placing it in the top 32.7%.
Is AstraZeneca Pharma India's Debt-to-Equity too high?
AstraZeneca Pharma India's current Debt-to-Equity of 0.13 is 333% above median its 10-year median of 0.03. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.13. The Drug Manufacturers industry median Debt-to-Equity is 0.27. AstraZeneca Pharma India's value of 0.13 is 51.9% below this industry median. Based on the distribution chart, AstraZeneca Pharma India ranks #266 out of 814 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, AstraZeneca Pharma India has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, AstraZeneca Pharma India ranks #266 out of 814 companies for Debt-to-Equity. This puts AstraZeneca Pharma India in the upper half of its industry. The industry median Debt-to-Equity is 0.27. AstraZeneca Pharma India's value of 0.13 is 51.9% below this benchmark. Historically, AstraZeneca Pharma India's own Debt-to-Equity has ranged from 0.01 to 0.13 over the past decade. While the company's 10-year median is 0.03 vs. the industry median of 0.27, AstraZeneca Pharma India has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AstraZeneca Pharma India's current Debt-to-Equity of 0.13 is 51.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on AstraZeneca Pharma India and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AstraZeneca Pharma India's current Debt-to-Equity is 0.13, which is 333% above median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹11,052.50, compared to a current price of ₹8,094.50 — trading 26.8% below its estimated fair value. The current Debt-to-Equity is 0.13, which is 333% above median its 10-year median of 0.03 and 51.9% below the Drug Manufacturers industry median of 0.27. AstraZeneca Pharma India's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current Debt-to-Equity is 0.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued.
The current stock price of ₹8,094.50 is trading 26.8% below its estimated GF Value™ of ₹11,052.50.
GuruFocus considers AstraZeneca Pharma India to be Modestly Undervalued.
Key valuation signals for NSE:ASTRAZEN:
Debt-to-Equity: 0.13 (333% above median its 10-year median of 0.03)
GF Value™: ₹11,052.50 vs. price of ₹8,094.50 (26.8% below fair value)
Industry Position: 51.9% below the Drug Manufacturers median (#266 of 814)
No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
90GF Score
Get the complete analysis for NSE:ASTRAZEN
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ASTRAZEN has been successfully added to your 
